Media Advisory - Oncolytics Biotech® Inc. to Present at RBC Capital Markets
2013 Healthcare Conference
CALGARY, Feb. 25, 2013
CALGARY, Feb. 25, 2013 /PRNewswire/ - Dr. Matt Coffey, Chief Operating Officer
of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present at the 2013
RBC Capital Markets Healthcare Conference on Tuesday, February 26, 2013 at
3:35 p.m. ET. The conference will take place on February 26^th and 27^th in
New York, NY.
A live audio link to the webcast presentation is available at:
http://www.veracast.com/webcasts/rbc/healthcare2013/71114328.cfm or on the
company's website at http://www.oncolyticsbiotech.com/presentations. It is
recommended that listeners log on 10 minutes in advance of the presentation to
register and download any necessary software.
An audio replay will be accessible approximately one hour following the
presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of human trials including a Phase III trial in head
and neck cancers using REOLYSIN^®, its proprietary formulation of the human
reovirus. For further information about Oncolytics, please visit:
The presentation and webcast times are subject to change. This release and the
presentation related thereto contain forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not under the
Company's control and which may cause actual results, performance or
achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN as a
cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except
as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
The Equicom Group
300 5^th Ave. SW, 10^th Floor
Calgary, Alberta, T2P 3C4
Dian Griesel, Inc.
396 West Broadway, 2^nd Floor
New York, NY 10012
Press spacebar to pause and continue. Press esc to stop.